- Home
- OKYO vs STTK Comparison
OKYO vs STTK Comparison
Compare OKYO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- STTK
- Stock Information
- Founded
- OKYO 2007
- STTK 2016
- Country
- OKYO United Kingdom
- STTK United States
- Employees
- OKYO N/A
- STTK N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- STTK Health Care
- Exchange
- OKYO Nasdaq
- STTK Nasdaq
- Market Cap
- OKYO 97.8M
- STTK 112.6M
- IPO Year
- OKYO 2022
- STTK 2020
- Fundamental
- Price
- OKYO $2.22
- STTK $1.92
- Analyst Decision
- OKYO Strong Buy
- STTK Hold
- Analyst Count
- OKYO 1
- STTK 5
- Target Price
- OKYO $7.00
- STTK $3.00
- AVG Volume (30 Days)
- OKYO 136.7K
- STTK 135.4K
- Earning Date
- OKYO 07-18-2025
- STTK 11-06-2025
- Dividend Yield
- OKYO N/A
- STTK N/A
- EPS Growth
- OKYO N/A
- STTK N/A
- EPS
- OKYO N/A
- STTK N/A
- Revenue
- OKYO N/A
- STTK $1,000,000.00
- Revenue This Year
- OKYO N/A
- STTK N/A
- Revenue Next Year
- OKYO N/A
- STTK N/A
- P/E Ratio
- OKYO N/A
- STTK N/A
- Revenue Growth
- OKYO N/A
- STTK N/A
- 52 Week Low
- OKYO $0.90
- STTK $0.69
- 52 Week High
- OKYO $3.35
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- OKYO 42.84
- STTK 47.53
- Support Level
- OKYO $2.33
- STTK $1.72
- Resistance Level
- OKYO $2.93
- STTK $2.06
- Average True Range (ATR)
- OKYO 0.22
- STTK 0.16
- MACD
- OKYO -0.05
- STTK -0.01
- Stochastic Oscillator
- OKYO 10.46
- STTK 50.70
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.